Gyre Therapeutics (NASDAQ:GYRE) Releases Earnings Results, Beats Expectations By $0.19 EPS

Gyre Therapeutics (NASDAQ:GYRE) released its earnings results on Thursday. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.19, Zacks reports. Gyre Therapeutics had a negative return on equity of 7.44% and a negative net margin of 14.80%. The business had revenue of $32.93 million for the quarter, compared to the consensus estimate of $28.40 million.

Gyre Therapeutics Stock Performance

Shares of GYRE traded up $0.75 during midday trading on Friday, reaching $4.76. The stock had a trading volume of 359,716 shares, compared to its average volume of 172,317. The firm has a 50 day simple moving average of $6.51 and a 200-day simple moving average of $6.90. Gyre Therapeutics has a one year low of $3.97 and a one year high of $9.14.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Zacks Research raised Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gyre Therapeutics in a research report on Wednesday. Finally, Wall Street Zen upgraded Gyre Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Reduce”.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a biopharmaceutical company focused on developing therapies for fibrotic diseases, including pulmonary and liver fibrosis. The company’s lead development program is F351, also known as hydronidone, an investigational small-molecule therapy designed to inhibit the progression of fibrosis.

F351 is being evaluated in clinical programs for idiopathic pulmonary fibrosis and liver fibrosis associated with chronic liver disease, including nonalcoholic steatohepatitis-related fibrosis.